US-based biotechnology company Trishula Therapeutics has reported positive results from its Phase I clinical trial of TTX-030, an anti-CD39 antibody designed to treat first-line metastatic pancreatic cancer.
The study assessed TTX-030 as a first-line treatment in combination with gemcitabine/nab-paclitaxel, both with and without the investigational anti-PD-1 antibody budigalimab, in patients with pancreatic adenocarcinoma.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The results showed an objective response rate (ORR) of 30%, median progression-free survival of 7.5 months, and median overall survival of 19.1 months in the efficacy-evaluable population.
Patients with high expression of the immune-associated biomarker HLA-DQ experienced a 46% ORR, as well as a median progression-free survival of 9.6 months and median overall survival of 21.9 months.
The treatment regimens were generally well-tolerated, with a low discontinuation rate due to adverse events. The most common side effects were in line with those expected from the standard chemotherapy used.
TTX-030 is now undergoing a global Phase II trial, ELTIVATE, which aims to further evaluate it as a first-line treatment for metastatic pancreatic adenocarcinoma.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial will enrol around 180 patients and focus on progression-free survival in a biomarker-enriched population.
TTX-030 operates by inhibiting CD39, an enzyme involved in converting adenosine triphosphate (ATP) to adenosine monophosphate (AMP), a process that can suppress immune response in the tumor microenvironment.
Trishula is developing the drug in partnership with AbbVie, with the aim of providing a new therapeutic option for patients with metastatic pancreatic cancer.
Trishula Therapeutics CEO Anil Singhal said: “The Phase I results demonstrated a strong median overall survival in patients with metastatic pancreatic cancer following treatment with TTX-030 combinations as well as marked benefit in those with high levels of tumour HLA-DQ biomarker expression.
“These findings have led to our currently enrolling global, randomised Phase II ELTIVATE study, with results expected in 2026.”
